A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT04229004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives * To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. * To determine progression-free survival (PFS) for each investigational arm vs. SOC. * To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). * To determine rates of clinical benefit; duration of clinical benefit.
Study identification
- NCT ID
- NCT04229004
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 502 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2020 (Actual)
- Primary completion
- Feb 5, 2025 (Actual)
- Completion
- Feb 5, 2025 (Actual)
- Last update posted
- Apr 6, 2025
2020 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego (UCSD) - Moores Cancer Center | La Jolla | California | 92037 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048-1804 | — |
| University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| University of Florida College of Medicine | Gainesville | Florida | 32610 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136-1002 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan - Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Cancer Center (MCCC) | Rochester | Minnesota | 55905-0001 | — |
| Siteman Cancer Center - Washington University Medical Campus | St Louis | Missouri | 63110-1010 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | — |
| New York University Langone Medical Center - Perlmutter Cancer Center | New York | New York | 10016 | — |
| Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Physicians - Solid Tumor/Gastrointestinal Oncology | New York | New York | 10065 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| University of Pennsylvania - Abramson Cancer Center | Philadelphia | Pennsylvania | 19104-5127 | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Baylor College of Medicine | Houston | Texas | 77030-3411 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Commonwealth University School of Medicine | Richmond | Virginia | 23219 | — |
| Virginia Mason Hospital & Seattle Medical Center | Seattle | Washington | 98101 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04229004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04229004 live on ClinicalTrials.gov.